TOP CATEGORY: Chemicals & Materials | Life Sciences | Banking & Finance | ICT Media

Global Flu RNA Vaccines Market Research Report 2022

Global Flu RNA Vaccines Market Research Report 2022

  • Category:Life Sciences
  • Published on : 22 September 2022
  • Pages :92
  • Formats:
  • Report Code:SMR-7376535
OfferClick for best price

Best Price: $2320

Flu RNA Vaccines Market Size, Share 2022


Market Analysis and Insights: Global Flu RNA Vaccines Market

The global Flu RNA Vaccines market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027.

With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Flu RNA Vaccines market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Flu RNA Vaccines market in terms of revenue.

On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Flu RNA Vaccines market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Flu RNA Vaccines market.

Global Flu RNA Vaccines Scope and Market Size

The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2017 to 2028. Understanding the segments helps in identifying the importance of different factors that aid the market growth.

Segment by Type

Segment by Application

  • Hospitals
  • Vaccination Center
  • Specialized Clinics
  • Hospital Pharmacy
  • Others

By Region

  • North America
  • United States
  • Canada
  • Europe
  • Germany
  • France
  • U.K.
  • Italy
  • Russia
  • Asia-Pacific
  • China
  • Japan
  • South Korea
  • India
  • Australia
  • China Taiwan
  • Indonesia
  • Thailand
  • Malaysia
  • Latin America
  • Mexico
  • Brazil
  • Argentina
  • Colombia
  • Middle East & Africa
  • Turkey
  • Saudi Arabia
  • UAE

By Company

  • Sanofi Pasteur Inc.
  • AstraZeneca
  • CSL Ltd.
  • Abbott
  • GlaxoSmithKline Plc.
  • Serum Institute of India Pvt. Ltd.
  • Pfizer
  • BioNTech
  • F.Hoffman La Roche Ltd
  • Novartis
  • Sinnovac Biotech Ltd
  • Moderna Therapeutics
  • CureVac

The information for each competitor/Company Profile includes:

  • Company Overview
  • Business Strategy
  • Key Product Offerings
  • Financial Performance
  • Key Performance Indicators
  • Risk Analysis
  • Recent Development
  • Regional Presence
  • SWOT Analysis 

The content of the study subjects includes a total of 15 chapters:

Chapter 1, describes Flu RNA Vaccines product scope, market overview, market opportunities, market driving force, and market risks.

Chapter 2, profiles the top manufacturers of Flu RNA Vaccines, with price, sales, revenue, and global market share of Flu RNA Vaccines from 2019 to 2022.

Chapter 3, the Flu RNA Vaccines competitive situation, sales, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.

Chapter 4, the Flu RNA Vaccines breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2017 to 2028.

Chapters 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, and application, from 2017 to 2028.

Chapters 7, 8, 9, 10, and 11, to break the sales data at the country level, with sales, revenue, and market share for key countries in the world, from 2017 to 2022. and the Flu RNA Vaccines market forecast, by regions, type, and application, with sales and revenue, from 2023 to 2028.

Chapter 12, the key raw materials and key suppliers, and industry chain of Flu RNA Vaccines.

Chapter 13, 14, and 15, to describe Flu RNA Vaccines sales channel, distributors, customers, research findings and conclusion, appendix and data source.

Key Indicators Analysed:

  • Market Players & Competitor Analysis: The report covers the key players of the industry including Company Profile, Product Specifications, Production Capacity/Sales, Revenue, Price and Gross Margin 2016-2027 & Sales with a thorough analysis of the market?s competitive landscape and detailed information on vendors and comprehensive details of factors that will challenge the growth of major market vendors.
  • Global and Regional Market Analysis: The report includes Global & Regional market status and outlook 2016-2027. Further the report provides break down details about each region & countries covered in the report. Identifying its sales, sales volume & revenue forecast. With detailed analysis by types and applications.
  • Market Trends: Market key trends which include Increased Competition and Continuous Innovations.
  • Opportunities and Drivers: Identifying the Growing Demands and New Technology
  • Porters Five Force Analysis: The report provides with the state of competition in industry depending on five basic forces: threat of new entrants, bargaining power of suppliers, bargaining power of buyers, threat of substitute products or services, and existing industry rivalry.

Reasons to Purchase this Report:

  • Estimates 2022-2027 2021-2025 Flu RNA Vaccines Report on, Status and Forecast, by Players, Types and Applications market development trends with the recent trends and SWOT analysis
  • Market dynamics scenario, along with growth opportunities of the market in the years to come
  • Market segmentation analysis including qualitative and quantitative research incorporating the impact of economic and policy aspects
  • Regional and country level analysis integrating the demand and supply forces that are influencing the growth of the market.
  • Market value (USD Million) and volume (Units Million) data for each segment and sub-segment
  • Competitive landscape involving the market share of major players, along with the new projects and strategies adopted by players in the past five years
  • Comprehensive company profiles covering the product offerings, key financial information, recent developments, SWOT analysis, and strategies employed by the major market players
  • 1-year analyst support, along with the data support in excel format.

Research Methodology:

The research methodology used to estimate and forecast this market begins by capturing the revenues of the key players and their shares in the market. Various secondary sources such as press releases, annual reports, non-profit organizations, industry associations, governmental agencies and customs data, have been used to identify and collect information useful for this extensive commercial study of the market. Calculations based on this led to the overall market size. After arriving at the overall market size, the total market has been split into several segments and subsegments, which have then been verified through primary research by conducting extensive interviews with industry experts such as CEOs, VPs, directors, and executives. The data triangulation and market breakdown procedures have been employed to complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments.

Report Attributes Report Details
Report Title Global Flu RNA Vaccines Market Research Report 2022
Historical Year 2018 to 2022 (Data from 2010 can be provided as per availability)
Base Year 2021
Forecast Year 2029
Number of Pages 92 Pages
Customization Available Yes, the report can be customized as per your need.

TABLE OF CONTENTS

1 Flu RNA Vaccines Market Overview
1.1 Product Overview and Scope of Flu RNA Vaccines
1.2 Flu RNA Vaccines Segment by Type
1.2.1 Global Flu RNA Vaccines Sales Growth Rate Comparison by Type (2022-2028)
1.2.2 Non-Replicating mRNA
1.2.3 In Vivo Self-Replicating mRNA
1.2.4 In Vitro Dendritic Cell Non-Replicating mRNA Vaccine
1.2.5 Others
1.3 Flu RNA Vaccines Segment by Application
1.3.1 Global Flu RNA Vaccines Sales Comparison by Application: (2022-2028)
1.3.2 Hospitals
1.3.3 Vaccination Center
1.3.4 Specialized Clinics
1.3.5 Hospital Pharmacy
1.3.6 Others
1.4 Global Flu RNA Vaccines Market Size Estimates and Forecasts
1.4.1 Global Flu RNA Vaccines Revenue 2017-2028
1.4.2 Global Flu RNA Vaccines Sales 2017-2028
1.4.3 Flu RNA Vaccines Market Size by Region: 2017 Versus 2021 Versus 2028
2 Flu RNA Vaccines Market Competition by Manufacturers
2.1 Global Flu RNA Vaccines Sales Market Share by Manufacturers (2017-2022)
2.2 Global Flu RNA Vaccines Revenue Market Share by Manufacturers (2017-2022)
2.3 Global Flu RNA Vaccines Average Price by Manufacturers (2017-2022)
2.4 Manufacturers Flu RNA Vaccines Manufacturing Sites, Area Served, Product Type
2.5 Flu RNA Vaccines Market Competitive Situation and Trends
2.5.1 Flu RNA Vaccines Market Concentration Rate
2.5.2 The Global Top 5 and Top 10 Largest Flu RNA Vaccines Players Market Share by Revenue
2.5.3 Global Flu RNA Vaccines Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.6 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Flu RNA Vaccines Retrospective Market Scenario by Region
3.1 Global Flu RNA Vaccines Retrospective Market Scenario in Sales by Region: 2017-2022
3.2 Global Flu RNA Vaccines Retrospective Market Scenario in Revenue by Region: 2017-2022
3.3 North America Flu RNA Vaccines Market Facts & Figures by Country
3.3.1 North America Flu RNA Vaccines Sales by Country
3.3.2 North America Flu RNA Vaccines Revenue by Country
3.3.3 United States
3.3.4 Canada
3.4 Europe Flu RNA Vaccines Market Facts & Figures by Country
3.4.1 Europe Flu RNA Vaccines Sales by Country
3.4.2 Europe Flu RNA Vaccines Revenue by Country
3.4.3 Germany
3.4.4 France
3.4.5 U.K.
3.4.6 Italy
3.4.7 Russia
3.5 Asia Pacific Flu RNA Vaccines Market Facts & Figures by Region
3.5.1 Asia Pacific Flu RNA Vaccines Sales by Region
3.5.2 Asia Pacific Flu RNA Vaccines Revenue by Region
3.5.3 China
3.5.4 Japan
3.5.5 South Korea
3.5.6 India
3.5.7 Australia
3.5.8 China Taiwan
3.5.9 Indonesia
3.5.10 Thailand
3.5.11 Malaysia
3.6 Latin America Flu RNA Vaccines Market Facts & Figures by Country
3.6.1 Latin America Flu RNA Vaccines Sales by Country
3.6.2 Latin America Flu RNA Vaccines Revenue by Country
3.6.3 Mexico
3.6.4 Brazil
3.6.5 Argentina
3.6.6 Colombia
3.7 Middle East and Africa Flu RNA Vaccines Market Facts & Figures by Country
3.7.1 Middle East and Africa Flu RNA Vaccines Sales by Country
3.7.2 Middle East and Africa Flu RNA Vaccines Revenue by Country
3.7.3 Turkey
3.7.4 Saudi Arabia
3.7.5 UAE
4 Global Flu RNA Vaccines Historic Market Analysis by Type
4.1 Global Flu RNA Vaccines Sales Market Share by Type (2017-2022)
4.2 Global Flu RNA Vaccines Revenue Market Share by Type (2017-2022)
4.3 Global Flu RNA Vaccines Price by Type (2017-2022)
5 Global Flu RNA Vaccines Historic Market Analysis by Application
5.1 Global Flu RNA Vaccines Sales Market Share by Application (2017-2022)
5.2 Global Flu RNA Vaccines Revenue Market Share by Application (2017-2022)
5.3 Global Flu RNA Vaccines Price by Application (2017-2022)
6 Key Companies Profiled
6.1 Sanofi Pasteur Inc.
6.1.1 Sanofi Pasteur Inc. Corporation Information
6.1.2 Sanofi Pasteur Inc. Description and Business Overview
6.1.3 Sanofi Pasteur Inc. Flu RNA Vaccines Sales, Revenue and Gross Margin (2017-2022)
6.1.4 Sanofi Pasteur Inc. Flu RNA Vaccines Product Portfolio
6.1.5 Sanofi Pasteur Inc. Recent Developments/Updates
6.2 AstraZeneca
6.2.1 AstraZeneca Corporation Information
6.2.2 AstraZeneca Description and Business Overview
6.2.3 AstraZeneca Flu RNA Vaccines Sales, Revenue and Gross Margin (2017-2022)
6.2.4 AstraZeneca Flu RNA Vaccines Product Portfolio
6.2.5 AstraZeneca Recent Developments/Updates
6.3 CSL Ltd.
6.3.1 CSL Ltd. Corporation Information
6.3.2 CSL Ltd. Description and Business Overview
6.3.3 CSL Ltd. Flu RNA Vaccines Sales, Revenue and Gross Margin (2017-2022)
6.3.4 CSL Ltd. Flu RNA Vaccines Product Portfolio
6.3.5 CSL Ltd. Recent Developments/Updates
6.4 Abbott
6.4.1 Abbott Corporation Information
6.4.2 Abbott Description and Business Overview
6.4.3 Abbott Flu RNA Vaccines Sales, Revenue and Gross Margin (2017-2022)
6.4.4 Abbott Flu RNA Vaccines Product Portfolio
6.4.5 Abbott Recent Developments/Updates
6.5 GlaxoSmithKline Plc.
6.5.1 GlaxoSmithKline Plc. Corporation Information
6.5.2 GlaxoSmithKline Plc. Description and Business Overview
6.5.3 GlaxoSmithKline Plc. Flu RNA Vaccines Sales, Revenue and Gross Margin (2017-2022)
6.5.4 GlaxoSmithKline Plc. Flu RNA Vaccines Product Portfolio
6.5.5 GlaxoSmithKline Plc. Recent Developments/Updates
6.6 Serum Institute of India Pvt. Ltd.
6.6.1 Serum Institute of India Pvt. Ltd. Corporation Information
6.6.2 Serum Institute of India Pvt. Ltd. Description and Business Overview
6.6.3 Serum Institute of India Pvt. Ltd. Flu RNA Vaccines Sales, Revenue and Gross Margin (2017-2022)
6.6.4 Serum Institute of India Pvt. Ltd. Flu RNA Vaccines Product Portfolio
6.6.5 Serum Institute of India Pvt. Ltd. Recent Developments/Updates
6.7 Pfizer
6.6.1 Pfizer Corporation Information
6.6.2 Pfizer Description and Business Overview
6.6.3 Pfizer Flu RNA Vaccines Sales, Revenue and Gross Margin (2017-2022)
6.4.4 Pfizer Flu RNA Vaccines Product Portfolio
6.7.5 Pfizer Recent Developments/Updates
6.8 BioNTech
6.8.1 BioNTech Corporation Information
6.8.2 BioNTech Description and Business Overview
6.8.3 BioNTech Flu RNA Vaccines Sales, Revenue and Gross Margin (2017-2022)
6.8.4 BioNTech Flu RNA Vaccines Product Portfolio
6.8.5 BioNTech Recent Developments/Updates
6.9 F.Hoffman La Roche Ltd
6.9.1 F.Hoffman La Roche Ltd Corporation Information
6.9.2 F.Hoffman La Roche Ltd Description and Business Overview
6.9.3 F.Hoffman La Roche Ltd Flu RNA Vaccines Sales, Revenue and Gross Margin (2017-2022)
6.9.4 F.Hoffman La Roche Ltd Flu RNA Vaccines Product Portfolio
6.9.5 F.Hoffman La Roche Ltd Recent Developments/Updates
6.10 Novartis
6.10.1 Novartis Corporation Information
6.10.2 Novartis Description and Business Overview
6.10.3 Novartis Flu RNA Vaccines Sales, Revenue and Gross Margin (2017-2022)
6.10.4 Novartis Flu RNA Vaccines Product Portfolio
6.10.5 Novartis Recent Developments/Updates
6.11 Sinnovac Biotech Ltd
6.11.1 Sinnovac Biotech Ltd Corporation Information
6.11.2 Sinnovac Biotech Ltd Flu RNA Vaccines Description and Business Overview
6.11.3 Sinnovac Biotech Ltd Flu RNA Vaccines Sales, Revenue and Gross Margin (2017-2022)
6.11.4 Sinnovac Biotech Ltd Flu RNA Vaccines Product Portfolio
6.11.5 Sinnovac Biotech Ltd Recent Developments/Updates
6.12 Moderna Therapeutics
6.12.1 Moderna Therapeutics Corporation Information
6.12.2 Moderna Therapeutics Flu RNA Vaccines Description and Business Overview
6.12.3 Moderna Therapeutics Flu RNA Vaccines Sales, Revenue and Gross Margin (2017-2022)
6.12.4 Moderna Therapeutics Flu RNA Vaccines Product Portfolio
6.12.5 Moderna Therapeutics Recent Developments/Updates
6.13 CureVac
6.13.1 CureVac Corporation Information
6.13.2 CureVac Flu RNA Vaccines Description and Business Overview
6.13.3 CureVac Flu RNA Vaccines Sales, Revenue and Gross Margin (2017-2022)
6.13.4 CureVac Flu RNA Vaccines Product Portfolio
6.13.5 CureVac Recent Developments/Updates
7 Flu RNA Vaccines Manufacturing Cost Analysis
7.1 Flu RNA Vaccines Key Raw Materials Analysis
7.1.1 Key Raw Materials
7.1.2 Key Suppliers of Raw Materials
7.2 Proportion of Manufacturing Cost Structure
7.3 Manufacturing Process Analysis of Flu RNA Vaccines
7.4 Flu RNA Vaccines Industrial Chain Analysis
8 Marketing Channel, Distributors and Customers
8.1 Marketing Channel
8.2 Flu RNA Vaccines Distributors List
8.3 Flu RNA Vaccines Customers
9 Flu RNA Vaccines Market Dynamics
9.1 Flu RNA Vaccines Industry Trends
9.2 Flu RNA Vaccines Market Drivers
9.3 Flu RNA Vaccines Market Challenges
9.4 Flu RNA Vaccines Market Restraints
10 Global Market Forecast
10.1 Flu RNA Vaccines Market Estimates and Projections by Type
10.1.1 Global Forecasted Sales of Flu RNA Vaccines by Type (2023-2028)
10.1.2 Global Forecasted Revenue of Flu RNA Vaccines by Type (2023-2028)
10.2 Flu RNA Vaccines Market Estimates and Projections by Application
10.2.1 Global Forecasted Sales of Flu RNA Vaccines by Application (2023-2028)
10.2.2 Global Forecasted Revenue of Flu RNA Vaccines by Application (2023-2028)
10.3 Flu RNA Vaccines Market Estimates and Projections by Region
10.3.1 Global Forecasted Sales of Flu RNA Vaccines by Region (2023-2028)
10.3.2 Global Forecasted Revenue of Flu RNA Vaccines by Region (2023-2028)
11 Research Finding and Conclusion
12 Methodology and Data Source
12.1 Methodology/Research Approach
12.1.1 Research Programs/Design
12.1.2 Market Size Estimation
12.1.3 Market Breakdown and Data Triangulation
12.2 Data Source
12.2.1 Secondary Sources
12.2.2 Primary Sources
12.3 Author List
12.4 Disclaimer

LIST OF TABLES & FIGURES

List of Tables
Table 1. Global Flu RNA Vaccines Sales Growth Rate Comparison by Type (2022-2028) & (K Units) & (US$ Million)
Table 2. Global Flu RNA Vaccines Sales Growth Rate Comparison by Application (2022-2028) & (K Units) & (US$ Million)
Table 3. Global Flu RNA Vaccines Market Size by Region (US$ Million) (2017 VS 2021 VS 2028)
Table 4. Global Flu RNA Vaccines Market Competitive Situation by Manufacturers in 2021
Table 5. Global Flu RNA Vaccines Sales (K Units) of Key Manufacturers (2017-2022)
Table 6. Global Flu RNA Vaccines Sales Market Share by Manufacturers (2017-2022)
Table 7. Global Flu RNA Vaccines Revenue (US$ Million) by Manufacturers (2017-2022)
Table 8. Global Flu RNA Vaccines Revenue Share by Manufacturers (2017-2022)
Table 9. Global Market Flu RNA Vaccines Average Price (US$/Unit) of Key Manufacturers (2017-2022)
Table 10. Manufacturers Flu RNA Vaccines Manufacturing Sites and Area Served
Table 11. Manufacturers Flu RNA Vaccines Product Type
Table 12. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 13. Global Flu RNA Vaccines by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Flu RNA Vaccines as of 2021)
Table 14. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 15. Global Flu RNA Vaccines Sales by Region (2017-2022) & (K Units)
Table 16. Global Flu RNA Vaccines Sales Market Share by Region (2017-2022)
Table 17. Global Flu RNA Vaccines Revenue by Region (2017-2022) & (US$ Million)
Table 18. Global Flu RNA Vaccines Revenue Market Share by Region (2017-2022)
Table 19. North America Flu RNA Vaccines Sales by Country (2017-2022) & (K Units)
Table 20. North America Flu RNA Vaccines Sales Market Share by Country (2017-2022)
Table 21. North America Flu RNA Vaccines Revenue by Country (2017-2022) & (US$ Million)
Table 22. North America Flu RNA Vaccines Revenue Market Share by Country (2017-2022)
Table 23. Europe Flu RNA Vaccines Sales by Country (2017-2022) & (K Units)
Table 24. Europe Flu RNA Vaccines Sales Market Share by Country (2017-2022)
Table 25. Europe Flu RNA Vaccines Revenue by Country (2017-2022) & (US$ Million)
Table 26. Europe Flu RNA Vaccines Revenue Market Share by Country (2017-2022)
Table 27. Asia Pacific Flu RNA Vaccines Sales by Region (2017-2022) & (K Units)
Table 28. Asia Pacific Flu RNA Vaccines Sales Market Share by Region (2017-2022)
Table 29. Asia Pacific Flu RNA Vaccines Revenue by Region (2017-2022) & (US$ Million)
Table 30. Asia Pacific Flu RNA Vaccines Revenue Market Share by Region (2017-2022)
Table 31. Latin America Flu RNA Vaccines Sales by Country (2017-2022) & (K Units)
Table 32. Latin America Flu RNA Vaccines Sales Market Share by Country (2017-2022)
Table 33. Latin America Flu RNA Vaccines Revenue by Country (2017-2022) & (US$ Million)
Table 34. Latin America Flu RNA Vaccines Revenue Market Share by Country (2017-2022)
Table 35. Middle East and Africa Flu RNA Vaccines Sales by Country (2017-2022) & (K Units)
Table 36. Middle East and Africa Flu RNA Vaccines Sales Market Share by Country (2017-2022)
Table 37. Middle East and Africa Flu RNA Vaccines Revenue by Country (2017-2022) & (US$ Million)
Table 38. Middle East and Africa Flu RNA Vaccines Revenue Market Share by Country (2017-2022)
Table 39. Global Flu RNA Vaccines Sales by Type (2017-2022) & (K Units)
Table 40. Global Flu RNA Vaccines Sales Market Share by Type (2017-2022)
Table 41. Global Flu RNA Vaccines Revenue by Type (2017-2022) & (US$ Million)
Table 42. Global Flu RNA Vaccines Revenue Share by Type (2017-2022)
Table 43. Global Flu RNA Vaccines Price by Type (2017-2022) & (US$/Unit)
Table 44. Global Flu RNA Vaccines Sales (K Units) by Application (2017-2022)
Table 45. Global Flu RNA Vaccines Sales Market Share by Application (2017-2022)
Table 46. Global Flu RNA Vaccines Revenue by Application (2017-2022) & (US$ Million)
Table 47. Global Flu RNA Vaccines Revenue Share by Application (2017-2022)
Table 48. Global Flu RNA Vaccines Price by Application (2017-2022) & (US$/Unit)
Table 49. Sanofi Pasteur Inc. Corporation Information
Table 50. Sanofi Pasteur Inc. Description and Business Overview
Table 51. Sanofi Pasteur Inc. Flu RNA Vaccines Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 52. Sanofi Pasteur Inc. Flu RNA Vaccines Product
Table 53. Sanofi Pasteur Inc. Recent Developments/Updates
Table 54. AstraZeneca Corporation Information
Table 55. AstraZeneca Description and Business Overview
Table 56. AstraZeneca Flu RNA Vaccines Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 57. AstraZeneca Flu RNA Vaccines Product
Table 58. AstraZeneca Recent Developments/Updates
Table 59. CSL Ltd. Corporation Information
Table 60. CSL Ltd. Description and Business Overview
Table 61. CSL Ltd. Flu RNA Vaccines Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 62. CSL Ltd. Flu RNA Vaccines Product
Table 63. CSL Ltd. Recent Developments/Updates
Table 64. Abbott Corporation Information
Table 65. Abbott Description and Business Overview
Table 66. Abbott Flu RNA Vaccines Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 67. Abbott Flu RNA Vaccines Product
Table 68. Abbott Recent Developments/Updates
Table 69. GlaxoSmithKline Plc. Corporation Information
Table 70. GlaxoSmithKline Plc. Description and Business Overview
Table 71. GlaxoSmithKline Plc. Flu RNA Vaccines Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 72. GlaxoSmithKline Plc. Flu RNA Vaccines Product
Table 73. GlaxoSmithKline Plc. Recent Developments/Updates
Table 74. Serum Institute of India Pvt. Ltd. Corporation Information
Table 75. Serum Institute of India Pvt. Ltd. Description and Business Overview
Table 76. Serum Institute of India Pvt. Ltd. Flu RNA Vaccines Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 77. Serum Institute of India Pvt. Ltd. Flu RNA Vaccines Product
Table 78. Serum Institute of India Pvt. Ltd. Recent Developments/Updates
Table 79. Pfizer Corporation Information
Table 80. Pfizer Description and Business Overview
Table 81. Pfizer Flu RNA Vaccines Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 82. Pfizer Flu RNA Vaccines Product
Table 83. Pfizer Recent Developments/Updates
Table 84. BioNTech Corporation Information
Table 85. BioNTech Description and Business Overview
Table 86. BioNTech Flu RNA Vaccines Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 87. BioNTech Flu RNA Vaccines Product
Table 88. BioNTech Recent Developments/Updates
Table 89. F.Hoffman La Roche Ltd Corporation Information
Table 90. F.Hoffman La Roche Ltd Description and Business Overview
Table 91. F.Hoffman La Roche Ltd Flu RNA Vaccines Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 92. F.Hoffman La Roche Ltd Flu RNA Vaccines Product
Table 93. F.Hoffman La Roche Ltd Recent Developments/Updates
Table 94. Novartis Corporation Information
Table 95. Novartis Description and Business Overview
Table 96. Novartis Flu RNA Vaccines Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 97. Novartis Flu RNA Vaccines Product
Table 98. Novartis Recent Developments/Updates
Table 99. Sinnovac Biotech Ltd Corporation Information
Table 100. Sinnovac Biotech Ltd Description and Business Overview
Table 101. Sinnovac Biotech Ltd Flu RNA Vaccines Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 102. Sinnovac Biotech Ltd Flu RNA Vaccines Product
Table 103. Sinnovac Biotech Ltd Recent Developments/Updates
Table 104. Moderna Therapeutics Corporation Information
Table 105. Moderna Therapeutics Description and Business Overview
Table 106. Moderna Therapeutics Flu RNA Vaccines Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 107. Moderna Therapeutics Flu RNA Vaccines Product
Table 108. Moderna Therapeutics Recent Developments/Updates
Table 109. CureVac Corporation Information
Table 110. CureVac Description and Business Overview
Table 111. CureVac Flu RNA Vaccines Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 112. CureVac Flu RNA Vaccines Product
Table 113. CureVac Recent Developments/Updates
Table 114. Production Base and Market Concentration Rate of Raw Material
Table 115. Key Suppliers of Raw Materials
Table 116. Flu RNA Vaccines Distributors List
Table 117. Flu RNA Vaccines Customers List
Table 118. Flu RNA Vaccines Market Trends
Table 119. Flu RNA Vaccines Market Drivers
Table 120. Flu RNA Vaccines Market Challenges
Table 121. Flu RNA Vaccines Market Restraints
Table 122. Global Flu RNA Vaccines Sales Forecast by Type (2023-2028) & (K Units)
Table 123. Global Flu RNA Vaccines Sales Market Share Forecast by Type (2023-2028)
Table 124. Global Flu RNA Vaccines Revenue Forecast by Type (2023-2028) & (US$ Million)
Table 125. Global Flu RNA Vaccines Revenue Market Share Forecast by Type (2023-2028)
Table 126. Global Flu RNA Vaccines Sales Forecast by Application (2023-2028) & (K Units)
Table 127. Global Flu RNA Vaccines Sales Market Share Forecast by Application (2023-2028)
Table 128. Global Flu RNA Vaccines Revenue Forecast by Application (2023-2028) & (US$ Million)
Table 129. Global Flu RNA Vaccines Revenue Market Share Forecast by Application (2023-2028)
Table 130. Global Flu RNA Vaccines Sales Forecast by Region (2023-2028) & (K Units)
Table 131. Global Flu RNA Vaccines Sales Market Share Forecast by Region (2023-2028)
Table 132. Global Flu RNA Vaccines Revenue Forecast by Region (2023-2028) & (US$ Million)
Table 133. Global Flu RNA Vaccines Revenue Market Share Forecast by Region (2023-2028)
Table 134. Research Programs/Design for This Report
Table 135. Key Data Information from Secondary Sources
Table 136. Key Data Information from Primary Sources
List of Figures
Figure 1. Product Picture of Flu RNA Vaccines
Figure 2. Global Flu RNA Vaccines Market Share by Type in 2021 & 2028
Figure 3. Non-Replicating mRNA Product Picture
Figure 4. In Vivo Self-Replicating mRNA Product Picture
Figure 5. In Vitro Dendritic Cell Non-Replicating mRNA Vaccine Product Picture
Figure 6. Others Product Picture
Figure 7. Global Flu RNA Vaccines Market Share by Application in 2021 & 2028
Figure 8. Hospitals
Figure 9. Vaccination Center
Figure 10. Specialized Clinics
Figure 11. Hospital Pharmacy
Figure 12. Others
Figure 13. Global Flu RNA Vaccines Revenue, (US$ Million), 2017 VS 2021 VS 2028
Figure 14. Global Flu RNA Vaccines Market Size (2017-2028) & (US$ Million)
Figure 15. Global Flu RNA Vaccines Sales (2017-2028) & (K Units)
Figure 16. Flu RNA Vaccines Sales Share by Manufacturers in 2021
Figure 17. Global Flu RNA Vaccines Revenue Share by Manufacturers in 2021
Figure 18. The Global 5 and 10 Largest Flu RNA Vaccines Players: Market Share by Revenue in 2021
Figure 19. Flu RNA Vaccines Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2017 VS 2021
Figure 20. Global Flu RNA Vaccines Sales Market Share by Region (2017-2022)
Figure 21. Global Flu RNA Vaccines Sales Market Share by Region in 2021
Figure 22. Global Flu RNA Vaccines Revenue Market Share by Region (2017-2022)
Figure 23. Global Flu RNA Vaccines Revenue Market Share by Region in 2021
Figure 24. United States Flu RNA Vaccines Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 25. Canada Flu RNA Vaccines Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 26. Germany Flu RNA Vaccines Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 27. France Flu RNA Vaccines Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 28. U.K. Flu RNA Vaccines Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 29. Italy Flu RNA Vaccines Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 30. Russia Flu RNA Vaccines Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 31. China Flu RNA Vaccines Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 32. Japan Flu RNA Vaccines Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 33. South Korea Flu RNA Vaccines Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 34. India Flu RNA Vaccines Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 35. Australia Flu RNA Vaccines Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 36. China Taiwan Flu RNA Vaccines Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 37. Indonesia Flu RNA Vaccines Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 38. Thailand Flu RNA Vaccines Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 39. Malaysia Flu RNA Vaccines Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 40. Mexico Flu RNA Vaccines Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 41. Brazil Flu RNA Vaccines Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 42. Argentina Flu RNA Vaccines Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 43. Colombia Flu RNA Vaccines Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 44. Turkey Flu RNA Vaccines Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 45. Saudi Arabia Flu RNA Vaccines Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 46. UAE Flu RNA Vaccines Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 47. Sales Market Share of Flu RNA Vaccines by Type (2017-2022)
Figure 48. Manufacturing Cost Structure of Flu RNA Vaccines
Figure 49. Manufacturing Process Analysis of Flu RNA Vaccines
Figure 50. Flu RNA Vaccines Industrial Chain Analysis
Figure 51. Channels of Distribution
Figure 52. Distributors Profiles
Figure 53. Bottom-up and Top-down Approaches for This Report
Figure 54. Data Triangulation
Figure 55. Key Executives Interviewed

REPORT PURCHASE OPTIONS

USD Single User Price
USD Multi User Price
USD Enterprise Price

---- OR ----

Frequently Asked Questions ?

  • Upto 24 hrs - Working days
  • Upto 48 hrs max - Weekends and public holidays
  • Single User License
    A license granted to one user. Rules or conditions might be applied for e.g. the use of electric files (PDFs) or printings, depending on product.

  • Multi user License
    A license granted to multiple users.

  • Site License
    A license granted to a single business site/establishment.

  • Corporate License, Global License
    A license granted to all employees within organisation access to the product.
  • Online Payments with PayPal and CCavenue
  • Wire Transfer/Bank Transfer
  • Email
  • Hard Copy

Our Key Features

  • Data Accuracy and Reliability
  • Data Security
  • Customized Research
  • Trustworthy
  • Competitive Offerings
check discount